The study successfully met its primary endpoint, demonstrating that the recombinant zoster vaccine (RZV) is non-inferior to placebo regarding the risk of disease flares in patients with autoimmune rheumatic diseases (AIRD). The flare rate was 14% in the vaccine group compared to 15% in the placebo group.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
